SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Vivimed Labs shines on getting approval from Uzbekistan government for two products

08 Mar 2021 Evaluate

Vivimed Labs is currently trading at Rs. 18.15, up by 0.85 points or 4.91% from its previous closing of Rs. 17.30 on the BSE.

The scrip opened at Rs. 17.40 and has touched a high and low of Rs. 18.60 and Rs. 17.40 respectively. So far 93731 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 2 has touched a 52 week high of Rs. 23.62 on 25-Aug-2020 and a 52 week low of Rs. 6.50 on 23-Mar-2020.

Last one week high and low of the scrip stood at Rs. 18.60 and Rs. 15.70 respectively. The current market cap of the company is Rs. 145.93 crore.

The promoters holding in the company stood at 32.79%, while Institutions and Non-Institutions held 3.22% and 63.99% respectively.

Vivimed Labs has received approval from the Uzbekistan government for two products. The company has received approval for Bilastin tablets, which are used for the treatment of allergic Rhino conjunctivitis and Urticaria. Vivimed has also received approval for Orzole combi, which is used to treat gastrointestinal infections such as acute diarrhoea or dysentery, gynaecological, lung and urinary infections.

Vivimed Labs is engaged in providing specialty chemicals and pharmaceuticals products. The company offers products for oral care, sun care, skin care, hair care, reversacol photochromic dyes, imaging chemicals and nisarg.

Vivimed Labs Share Price

7.79 0.37 (4.99%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×